Oral News and Research

RSS

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

With oral anticoagulant rivaroxaban set to be subsidised under the Pharmaceutical Benefits Scheme (PBS) for preventing stroke, NPS MedicineWise is urging people to talk to their doctor before stopping or making any changes to their anticoagulant medicines.

30 Jul 2013

FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.

30 Jul 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Glucose intolerance, insulin resistance not associated with pathological features of AD

Glucose intolerance or insulin resistance do not appear to be associated with pathological features of Alzheimer disease (AD) or detection of the accumulation of the brain protein β-amyloid (Αβ), according to a report published by JAMA Neurology, a JAMA Network publication.

30 Jul 2013

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals announced today that on July 26, 2013 it submitted its New Drug Application to the U.S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

30 Jul 2013

Prana announces dosing of first patient in PBT2 Phase II trial for Alzheimer’s disease

Prana Biotechnology today announced that the first patient has been dosed in the 12-month open label extension study with Alzheimer’s Disease patients participating in Prana’s Phase 2 IMAGINE trial.

29 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

Colgate reports worldwide Net sales of $4,346 million in second quarter 2013

Colgate-Palmolive Company today reported worldwide Net sales of $4,346 million in second quarter 2013, an increase of 2.0% versus second quarter 2012. Global unit volume grew 4.0%, pricing increased 1.0% and foreign exchange was negative 3.0%. Organic sales (Net sales excluding foreign exchange, acquisitions and divestments) grew 5.5%.

25 Jul 2013

Teleflex introduces Rusch TruLite Laryngoscope System

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has launched the Rusch TruLite Laryngoscope System, a disposable laryngoscope blade and handle system for single-patient use.

25 Jul 2013

NIAID researchers discover monoclonal antibody can neutralize human norovirus

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) provide the first proof of concept data showing that a monoclonal antibody can neutralize human norovirus. This research, which could one day lead to effective therapies against the virus, was published online ahead of print in the Journal of Virology.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

MUCMD Symposium to be held at The Saban Research Institute of Children's Hospital Los Angeles

On August 16 and 17, the 3rd annual Meaningful Use of Complex Medical Data Symposium is returning to The Saban Research Institute of Children's Hospital Los Angeles.

23 Jul 2013

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Researchers identify neural pathways involved in word learning among humans

For the first time scientists have identified how a pathway in the brain which is unique to humans allows us to learn new words. The average adult's vocabulary consists of about 30,000 words. This ability seems unique to humans as even the species closest to us -- chimps -- manage to learn no more than 100.

23 Jul 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.

22 Jul 2013

Oral News and Research

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

FDA accepts NDA for MNK-795 oral formulation

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Glucose intolerance, insulin resistance not associated with pathological features of AD

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Prana announces dosing of first patient in PBT2 Phase II trial for Alzheimer’s disease

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Colgate reports worldwide Net sales of $4,346 million in second quarter 2013

Teleflex introduces Rusch TruLite Laryngoscope System

NIAID researchers discover monoclonal antibody can neutralize human norovirus

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

MUCMD Symposium to be held at The Saban Research Institute of Children's Hospital Los Angeles

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Researchers identify neural pathways involved in word learning among humans

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Drug release of tramadol hydrochloride increases from 1.9 to 7.5 hours by adding Novozymes Biopharma’s Hyasis®

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News